Investors2020-08-11T15:16:10-04:00
Page-TitleINVESTORS

INVEST IN THE FUTURE OF PAIN RELIEF

Pain is universal. It disrupts work, time with family, and quality of life. Through innovations, we can make a difference.

VIRPAX Pharmaceuticals is collaborating with the best minds of the pharmaceutical industry. Working alongside these leaders, we can improve pain management and target pain at its source.

Partner with us as we develop the next generation of pharmaceutical products that can minimize pain and improve people’s lives.

BECOME A PARTNER

484.880.4588 info@virpaxpharma.com

Page-TitlePRODUCT PIPELINE

OUR CORPORATE GOVERNANCE

We are dedicated to helping people manage pain in an ethical and responsible way. We have strong policies in place that help us get there.

READ MORE
SubheadRECENT NEWS

Virpax’s MMS019 Inhibits SARS-COV-2 in Ex-Vivo Airway Model

Virpax® Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that based on recent ex-vivo studies, MMS019, a high-density mucoadhesive polymer, has demonstrated reduction of infectivity from respiratory viruses like influenza and SARS-COV-2. MMS019 contains a positively charged polymer that has been through [...]

December 7th, 2020|Press Release|

Virpax Enters into an NIH Collaboration to Further Develop NES100 for Acute and Chronic Non-Cancer Pain

Announces CRADA with National Center for Advancing Translational Sciences Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that it has entered into a cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the [...]

August 31st, 2020|Press Release|
More articles
Go to Top